ResearcherMedical University of SilesiaActive in the last 2 years
Michał Piątek
Matched on ORCID iD 0000-0002-2401-2116; OpenAlex author ID A5000237437. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 3
- Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma - a prospective s… Co-author DOI 10.5114/wo.2024.137760↗
- Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells. Co-author DOI 10.3390/biomedicines10071761↗
- Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? Co-author DOI 10.1016/j.critrevonc.2019.01.010↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sergiusz Nawrocki · 2 shared papers, 2019–2024 · strength 0.33
- Paper Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pan… DOI 10.5114/wo.2024.137760↗
- Paper Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? DOI 10.1016/j.critrevonc.2019.01.010↗
- Rafał Pęksa · 2 shared papers, 2019–2022 · strength 0.29
- Paper Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 … DOI 10.3390/biomedicines10071761↗
- Paper Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? DOI 10.1016/j.critrevonc.2019.01.010↗
- Paweł Lampe · 1 shared paper, 2024 · strength 0.22
- Sławomir Mrowiec · 1 shared paper, 2024 · strength 0.22
- Wojciech Biernat · 1 shared paper, 2022 · strength 0.17
- Stanisław Hać · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.